UPCC 53422: An Open-Label Phase I Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma The Protocol

Age
99 years or below
Gender
All
Location
1

Brief description of study

Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 14 Jun 2023. Study ID: 853191
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research